Patents by Inventor Erika Leemans

Erika Leemans has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Non-beta lactam antibiotics
    Patent number: 10662164
    Abstract: The invention provides a newly discovered oxadiazole class of antibiotics. The oxadiazoles impair cell-wall biosynthesis and exhibit activities against the Gram-positive bacteria such as the bacterium Staphylococcus aureus, including methicillin-resistant S. aureus (MRSA) and vancomycin-resistant and linezolid-resistant S. aureus. For example, 5-(1H-indol-5-yl)-3-(4-(4-(trifluoromethyl)phenoxy)phenyl)-1,2,4-oxadiazole (antibiotic 75b) was efficacious in a mouse model of MRSA infection, exhibiting a long half-life, a high volume of distribution, and low clearance. Antibiotic 75b antibiotic is bactericidal and is orally bioavailable. This class of antibiotics can be used as a therapeutic agent against infections by Gram-positive bacteria such as MRSA.
    Type: Grant
    Filed: September 25, 2015
    Date of Patent: May 26, 2020
    Assignee: University of Notre Dame du Lac
    Inventors: Mayland Chang, Shahriar Mobashery, Edward Spink, Derong Ding, Sebastian Testero, Erika Leemans, Marc Boudreau
  • NON-BETA LACTAM ANTIBIOTICS
    Publication number: 20190127340
    Abstract: The invention provides a newly discovered oxadiazole class of antibiotics. The oxadiazoles impair cell-wall biosynthesis and exhibit activities against the Gram-positive bacteria such as the bacterium Staphylococcus aureus, including methicillin-resistant S. aureus (MRSA) and vancomycin-resistant and linezolid-resistant S. aureus. For example, 5-(1H-indol-5-yl)-3-(4-(4-(trifluoromethyl)phenoxy)phenyl)-1,2,4-oxadiazole (antibiotic 75b) was efficacious in a mouse model of MRSA infection, exhibiting a long half-life, a high volume of distribution, and low clearance. Antibiotic 75b antibiotic is bactericidal and is orally bioavailable. This class of antibiotics can be used as a therapeutic agent against infections by Gram-positive bacteria such as MRSA.
    Type: Application
    Filed: September 25, 2015
    Publication date: May 2, 2019
    Inventors: Mayland CHANG, Shahriar Mobashery, Edward Spink, Derong Ding, Sebastian Testero, Erika Leemans, Marc Boudreau